These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22902456)

  • 21. [A case of high CEA colon cancer responding to neoadjuvant chemotherapy with FOLFIRI].
    Nakajima S; Sonoda K; Kadokawa Y; Kawabe A; Yamamoto T; Egawa H
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1995-8. PubMed ID: 20948272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
    Takeuchi M; Ogata Y; Ishibashi N; Uchida S; Murakami N; Kibe S; Takahashi K; Yahara T; Shirouzu K
    Gan To Kagaku Ryoho; 2012 May; 39(5):843-6. PubMed ID: 22584346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
    Lieberman R
    Am J Ther; 2012 Nov; 19(6):395-6. PubMed ID: 23011178
    [No Abstract]   [Full Text] [Related]  

  • 26. [A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
    Tamura T; Ishikawa N; Koui S; Nakashima H; Minagawa N; Hachiya Y; Hirata K; Sako T; Fukuyama T; Hirano Y
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1813-6. PubMed ID: 20841954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
    Hoshino H; Ishii Y; Hasegawa H; Endo T; Ochiai H; Hoshino Y; Matsunaga A; Shigeta K; Seo Y; Hoshino G; Kitagawa Y
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):983-6. PubMed ID: 22705698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].
    Tagami Y; Ogata S; Katakawa M; Bando Y
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):317-9. PubMed ID: 22333652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
    Asai H; Shinozaki E; Nozaki A; Watanabe T; Suenaga M; Matuzaka S; Chin K; Mizunuma N; Yasukawa M; Hatake K
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1285-91. PubMed ID: 21829065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
    Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
    Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
    Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
    Hebbar M; Fournier P; Romano O
    Eur J Cancer Care (Engl); 2010 Mar; 19(2):167-71. PubMed ID: 19702696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)].
    Matsutani T; Sasajima K; Suzuki S; Matsushita A; Maruyama H; Matsuda A; Miyamoto M; Yokoyama T; Sugiura A; Yanagi K; Nishi Y; Arai H; Wakabayashi H; Tajiri T
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):505-7. PubMed ID: 19295282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer].
    Komaki C; Hanatate F; Kobayashi K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):113-6. PubMed ID: 21368470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
    Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
    Cheng AL; Li J; Vaid AK; Ma BB; Teh C; Ahn JB; Bello M; Charoentum C; Chen LT; de Lima Lopes G; Ho GF; Kong HL; Lam KO; Liu TS; Park YS; Sriuranpong V; Sudoyo AW; Wang JY; Zhang J; Zhang SZ; Ciardiello F; Köhne CH; Shaw M; Kim TW
    Clin Colorectal Cancer; 2014 Sep; 13(3):145-55. PubMed ID: 25209093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.